Tag: drug eluting stents

1. In this pre-specified ancillary study of a randomized control trial, ticagrelor alone after one month was found non-inferior, but not superior, to dual antiplatelet therapy in preventing ischemic events after drug eluting coronary stenting. 2. Ticagrelor did not decrease bleeding risk compared with dual antiplatelet therapy. Evidence Rating Level: 2...
While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of therapy remains controversial. American and European guidelines recommend DAPT for a minimum of 12 months for acute coronary syndrome (ACS), and at least 6 months in stable...
1. In comparison to everolimus-eluting metallic stents (EESs), bioresorbable vascular scaffolds (BVSs) increased the chances for thrombotic events at both mid- and long-term follow-up. 2. Compared to patients with EESs, those with BVSs had a heightened risk (that increased over time) of myocardial infarction, target lesion revascularization (TLR), and target...
1. Device thrombosis occurred at a higher rate in patients undergoing percutaneous coronary intervention (PCI) utilizing a bioabsorbable scaffold compared to a metallic stent, both of which were covered in everolimus. 2. Failure of vessel revascularization and cardiac death occurs at similar rates for PCI procedures utilizing bioresorbable scaffolds and...
1. A prediction model for assessing the harm and benefit of long-term dual antiplatelet therapy after percutaneous coronary intervention (PCI) was able to accurately identify patients with the highest risk of ischemia. 2. Patients with high-risk of ischemia after PCI who were maintained on aspirin and thienopyridine had a significantly...
1. After 12 months of dual antiplatelet therapy in patients who received drug eluting stents (DES), patients who continued on a thienopyridine in addition to aspirin for 18 months experienced significantly lower rates of stent thrombosis and myocardial infarction compared to those taking placebo. 2. The risk of bleeding was...
1. From a systematic review, longer duration dual-antiplatelet therapy was associated with a decreased risk of myocardial infarction in patients with drug-eluting stents. 2. However, longer duration therapy also increased the risk of major bleeding and all-cause mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with coronary artery disease (CAD) who...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: The Randomized, Multicenter ITALIC Trial Current national society guidelines recommend 12 months of dual antiplatelet therapy...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-Eluting Stents Use of dual antiplatelet therapy for up to one year after placement of a drug-eluting stent is standard practice, but the...
1. After 12 months of dual antiplatelet therapy, patients who continued on a thienopyridine in addition to aspirin for 18 months experienced significantly lower rates of stent thrombosis and myocardial infarction compared to those taking placebo. 2. The risk of bleeding was significantly higher in patients who continued on thienopyridine...